Johnson & Johnson (JNJ) income statement
NYSE · Healthcare · Drug Manufacturers - General · 141,700 employees · CEO Joaquin Duato
- Price
- $273.20 -0.73%
- Market cap
- $658B
- Enterprise value
- $685B
- Last report
- Q3 '26 filed 2026-10-21
- Next report
- 2027-01-26 EPS est. $2.91
Johnson & Johnson (JNJ) reported revenue of $25.4B for Q3 '26 (+5.9% year on year), operating income of $6.37B (25.1% of revenue) and net income of $210M. Over the last four quarters revenue was $99.3B.
Income statement
| Income statement | Trend | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.4B | $21.4B | $22.4B | $22.5B | $22.5B | $21.9B | $23.7B | $24B | $24.6B | $24.1B | $25.3B | $25.4B | |
| Cost of revenue | $6.8B | $6.51B | $6.87B | $6.96B | $7.13B | $7.36B | $7.63B | $7.3B | $7.97B | $8.11B | $8.05B | $6.86B | |
| Gross profit | $14.6B | $14.9B | $15.6B | $15.5B | $15.4B | $14.5B | $16.1B | $16.7B | $16.6B | $16B | $17.3B | $18.5B | |
| Research & development | $4.48B | $3.54B | $3.44B | $4.95B | $5.3B | $3.23B | $3.52B | $3.67B | $4.25B | $3.53B | $3.65B | $4.65B | |
| General & administrative | $5.51B | $5.06B | $5.48B | $5.28B | $6.25B | $5.01B | $5.79B | $5.92B | $0 | $0 | $0 | $0 | |
| Other operating expenses | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.24B | |
| Operating expenses | $9.99B | $8.6B | $8.92B | $10.2B | $11.6B | $8.24B | $9.31B | $9.59B | $11B | $9.56B | $10.1B | $12.2B | |
| Operating income | $4.61B | $6.27B | $6.66B | $5.28B | $3.84B | $6.3B | $6.81B | $7.1B | $5.59B | $6.4B | $7.17B | $6.37B | |
| Interest income | $363M | $364M | $395M | $292M | $281M | $332M | $260M | $227M | $237M | $229M | $219M | $0 | |
| Interest expense | $151M | $155M | $270M | $193M | $137M | $204M | $308M | $245M | $214M | $272M | $281M | $31M | |
| Other non-operating income (gains on investments, FX ...) | -$370M | $2.4B | $639M | $1.75B | -$183M | -$7.54B | $11M | -$415M | $411M | $133M | $146M | $0 | |
| Total non-operating income | $219M | -$2.56B | -$909M | -$1.94B | $46M | $7.33B | -$319M | $397M | -$625M | -$405M | -$427M | -$6.33B | |
| Income before tax | $4.83B | $3.71B | $5.75B | $3.34B | $3.89B | $13.6B | $6.49B | $7.49B | $4.97B | $5.99B | $6.75B | $34M | |
| Income tax | $694M | $459M | $1.06B | $644M | $456M | $2.63B | $954M | $2.34B | -$150M | $755M | $1.21B | -$176M | |
| Net income | $4.05B | $3.26B | $4.69B | $2.69B | $3.43B | $11B | $5.54B | $5.15B | $5.12B | $5.24B | $5.53B | $210M | |
| EPS (basic) | $1.68 | $1.35 | $1.95 | $1.12 | $1.43 | $4.57 | $2.29 | $2.14 | $2.10 | $2.14 | $2.27 | $0.09 | |
| EPS (diluted) | $1.67 | $1.34 | $1.93 | $1.11 | $1.41 | $4.54 | $2.29 | $2.12 | $2.10 | $2.14 | $2.27 | $0.09 | |
| Shares (basic, weighted) | 2.41B | 2.41B | 2.41B | 2.41B | 2.41B | 2.41B | 2.42B | 2.43B | 2.43B | 2.45B | 2.44B | 2.45B | |
| Shares (diluted, weighted) | 2.43B | 2.43B | 2.42B | 2.43B | 2.43B | 2.42B | 2.42B | 2.43B | 2.44B | 2.45B | 2.44B | 2.45B | |
| Depreciation & amortization | $1.84B | $1.82B | $1.78B | $1.85B | $1.9B | $1.77B | $1.94B | $1.78B | $2.01B | $2B | $1.96B | $0 | |
| EBITDA | $6.82B | $5.68B | $7.8B | $5.38B | $5.92B | $15.6B | $8.74B | $9.29B | $7.19B | $8.27B | $8.99B | $6.37B |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71.9B | $76.5B | $81.6B | $82.1B | $82.6B | $78.7B | $80B | $85.2B | $88.8B | $94.2B | |
| Cost of revenue | $21.8B | $25.4B | $27.1B | $27.6B | $28.4B | $23.4B | $24.6B | $26.6B | $27.5B | $30.3B | |
| Gross profit | $50.1B | $51B | $54.5B | $54.5B | $54.2B | $55.3B | $55.4B | $58.6B | $61.4B | $63.9B | |
| Research & development | $9.14B | $10.6B | $10.8B | $11.4B | $12.3B | $14.3B | $14.1B | $15.1B | $17.2B | $14.7B | |
| General & administrative | $20.1B | $21.5B | $22.5B | $22.2B | $22.1B | $20.1B | $20.2B | $20.1B | $22B | $0 | |
| Operating expenses | $29.2B | $32.1B | $33.3B | $33.5B | $34.4B | $34.4B | $34.4B | $35.2B | $39.2B | $38.3B | |
| Operating income | $20.9B | $18.9B | $21.2B | $21B | $19.7B | $20.9B | $21B | $23.4B | $22.1B | $25.6B | |
| Interest income | $368M | $385M | $611M | $357M | $111M | $53M | $490M | $1.26B | $1.33B | $1.06B | |
| Interest expense | $726M | $934M | $1.01B | $318M | $201M | $183M | $276M | $772M | $755M | $971M | |
| Other non-operating income (gains on investments, FX ...) | $362M | $290M | $2.17B | $3.32B | $3.04B | $1.58B | $1.38B | $7.58B | $4.71B | -$7.96B | |
| Total non-operating income | -$1.09B | -$1.22B | -$3.18B | -$3.64B | -$3.24B | -$1.77B | -$1.65B | -$8.35B | -$5.46B | $6.99B | |
| Income before tax | $19.8B | $17.7B | $18B | $17.3B | $16.5B | $19.2B | $19.4B | $15.1B | $16.7B | $32.6B | |
| Income tax | $3.26B | $16.4B | $2.7B | $2.21B | $1.78B | $1.38B | $2.99B | $1.74B | $2.62B | $5.78B | |
| Net income | $16.5B | $1.3B | $15.3B | $15.1B | $14.7B | $20.9B | $17.9B | $35.2B | $14.1B | $26.8B | |
| EPS (basic) | $6.08 | $0.48 | $5.75 | $5.74 | $5.59 | $7.93 | $6.83 | $13.88 | $5.84 | $11.03 | |
| EPS (diluted) | $5.93 | $0.47 | $5.61 | $5.63 | $5.51 | $7.81 | $6.73 | $13.72 | $5.79 | $11.03 | |
| Shares (basic, weighted) | 2.71B | 2.68B | 2.66B | 2.63B | 2.63B | 2.63B | 2.61B | 2.53B | 2.41B | 2.43B | |
| Shares (diluted, weighted) | 2.79B | 2.75B | 2.73B | 2.68B | 2.67B | 2.67B | 2.66B | 2.56B | 2.43B | 2.43B | |
| Depreciation & amortization | $3.75B | $5.64B | $6.93B | $7.01B | $7.23B | $7.39B | $6.97B | $7.49B | $7.34B | $7.5B | |
| EBITDA | $24.3B | $24.2B | $25.9B | $24.7B | $23.9B | $26.8B | $26.6B | $23.3B | $24.8B | $41.1B |
Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-27, 10-Q 2026-06-28, 10-Q 2026-03-29, 10-K 2025-12-28, 10-Q 2025-09-28, 10-Q 2025-06-29, 10-Q 2025-03-30, 10-K 2024-12-29, 10-Q 2024-09-29
Data as of 2026-11-01